Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Candel Therapeutics (Nasdaq: CADL) announced inducement stock option grants on March 31, 2026 to five new employees totaling 70,000 options at a $4.90 exercise price.
The options were granted under the company’s 2025 Inducement Plan, adopted December 24, 2025, and vest 25% after one year, then monthly over 36 months, subject to continued service.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – CADL
On the day this news was published, CADL gained 0.40%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: CAPR -1.08%, ANNX -5.72%, MNPR +1.28%, TNXP -0.51%, VNDA +0.86%. No clear sector-wide direction relative to CADL.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 17 | NSCLC survival update | Positive | +3.6% | Phase 2a NSCLC data showing 25.4-month median overall survival. |
| Mar 12 | Earnings and runway | Positive | -2.4% | Q4/FY 2025 results and cash runway into Q1 2028 with financing. |
| Mar 09 | Prostate cancer data | Positive | +3.9% | Planned presentation of extended Phase 3 prostate cancer trial data. |
| Mar 02 | Inducement option grant | Neutral | -3.9% | Inducement options for a new employee under 2025 Inducement Plan. |
| Feb 24 | Conference presentation | Positive | +2.4% | Announcement of presentation at TD Cowen health care conference. |
Recent clinically focused announcements with generally positive tone often saw modest positive price reactions, while a positive earnings/financing update drew a small decline.
Over the last six weeks, Candel reported multiple clinically oriented milestones and financing steps. A Mar 17 Phase 2a NSCLC survival update and a planned Phase 3 trial were followed by a +3.61% move. On Mar 12, Q4 and full‑year 2025 results plus funding extended runway into Q1 2028, yet shares fell 2.35%. Additional prostate cancer Phase 3 data, conference participation, and prior inducement grants produced mostly modest positive reactions, framing today’s routine option awards within an active clinical and capital-raising backdrop.
Regulatory & Risk Context
An effective Form S-3 shelf filed on Aug 14, 2025 allows Candel to offer up to $300,000,000 of securities, including up to $50,000,000 of common stock via an at-the-market agreement with Jefferies. Recent 424B5 usage in February 2026 indicates the company has already tapped this capacity for equity financing.
Market Pulse Summary
This announcement details standard inducement stock options for five new employees, totaling 70,000 shares at an exercise price of $4.90, vesting over up to four years under the 2025 Inducement Plan. It follows substantial February 2026 equity and royalty financings and builds on ongoing clinical progress in prostate and lung cancer. Investors may watch future filings for additional equity usage under the existing $300,000,000 shelf and for further clinical milestones that could reshape the risk‑reward profile.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
stock options financial
AI-generated analysis. Not financial advice.
NEEDHAM, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on March 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to five new employees, stock options to purchase an aggregate of 70,000 shares of the Company’s common stock, with a per share exercise price of
The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest with respect to
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by the Board on December 24, 2025.
About Candel Therapeutics
Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (CAN-2409 or aglatimagene) is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA). The FDA also granted Fast Track Designation, Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC.
Linoserpaturev (CAN-3110) is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma, evaluating the effects of repeat linoserpaturev injections. Initial results were published in Nature and Science Translational Medicine and linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
For more information about Candel, visit: www.candeltx.com
Investor Contact
Theodore Jenkins
Vice President, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com
Media Contact
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com
